The chemical class identified as UGT2B7 Inhibitors constitutes a group of compounds meticulously designed to selectively target the molecular entity UGT2B7, a member of the UDP-glucuronosyltransferase (UGT) superfamily. UGT2B7 plays a pivotal role in phase II metabolism, particularly in the glucuronidation of diverse endogenous and exogenous compounds. This enzymatic process involves the addition of a glucuronic acid moiety to substrates, facilitating their elimination from the body. While the broader UGT family is recognized for its involvement in xenobiotic metabolism, the specific substrate preferences and regulatory mechanisms associated with UGT2B7 are subjects of ongoing research within the fields of pharmacology and biochemistry. Inhibitors within the UGT2B7 Inhibitors class are intricately engineered molecules with the primary objective of modulating the activity or function of UGT2B7, thereby inducing an inhibitory effect. Researchers in this field adopt a multifaceted approach, integrating insights from structural biology, medicinal chemistry, and computational modeling to unravel the complex molecular interactions between the inhibitors and the target UGT2B7.
Structurally, UGT2B7 Inhibitors are characterized by specific molecular features designed to facilitate selective binding to UGT2B7. This selectivity is crucial to minimize unintended effects on other UGT isoforms or cellular components, ensuring a focused impact on the intended molecular target. The development of inhibitors within this chemical class involves a comprehensive exploration of structure-activity relationships, optimization of pharmacokinetic properties, and a deep understanding of the molecular mechanisms associated with UGT2B7. As researchers delve deeper into the functional aspects of UGT2B7 Inhibitors, the knowledge generated contributes not only to deciphering the specific roles of UDP-glucuronosyltransferase 2B7 but also to advancing our broader comprehension of drug metabolism, xenobiotic detoxification, and the intricate regulatory networks involved in cellular processes. The exploration of UGT2B7 Inhibitors stands as a significant avenue for expanding fundamental knowledge in pharmacology and biochemistry.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5,5-Diphenyl Hydantoin | 57-41-0 | sc-210385 | 5 g | $70.00 | ||
Phenytoin, an antiepileptic drug, has been reported to inhibit UGT2B7 expression possibly through nuclear receptor-mediated transcriptional repression. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Although primarily known as an inducer of some UGT enzymes, rifampicin can also competitively inhibit the expression of others, including UGT2B7. | ||||||
Ethynyl Estradiol | 57-63-6 | sc-205318 sc-205318A | 100 mg 500 mg | $20.00 $29.00 | 3 | |
As a synthetic estrogen, ethinylestradiol can modulate the expression of various enzymes, potentially including UGT2B7, through estrogen receptor-mediated pathways. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin influences a variety of signaling pathways and can modulate the expression of drug-metabolizing enzymes, including UGT2B7. | ||||||
Chloramphenicol | 56-75-7 | sc-3594 | 25 g | $90.00 | 10 | |
Chloramphenicol has been reported to inhibit the expression of certain UGT enzymes by interacting with ribosomal function and protein synthesis. | ||||||
Piperine | 94-62-2 | sc-205809 sc-205809A | 5 g 25 g | $37.00 $146.00 | 3 | |
Piperine is known to modulate various enzymes involved in drug metabolism, and it may reduce UGT2B7 expression by affecting transcriptional regulators. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin, a flavonoid, has the potential to inhibit UGT2B7 expression by modulating gene transcription through interaction with signaling pathways. | ||||||
Wogonin, S. baicalensis | 632-85-9 | sc-203313 | 10 mg | $200.00 | 8 | |
Wogonin can affect various enzymes and receptors, potentially downregulating UGT2B7 expression through direct or indirect interactions. | ||||||
Andrographolide | 5508-58-7 | sc-205594 sc-205594A | 50 mg 100 mg | $15.00 $40.00 | 7 | |
Andrographolide has been known to influence drug-metabolizing enzymes, potentially leading to decreased UGT2B7 expression. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
As a proton pump inhibitor, omeprazole can alter gastric pH, which may influence UGT2B7 expression indirectly through alterations in drug absorption and metabolism. | ||||||